{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-21-014445","form_type":"8-K","ticker":"TGTX","cik":"0001001316","company_name":"TG THERAPEUTICS, INC.","filed_at":"2021-11-04T23:59:59+00:00","discovered_at":"2026-05-14T18:04:10.976327+00:00","generated_at":"2026-06-28T12:28:53.634904+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"TG Therapeutics Q3 net loss $85.6M; UKONIQ revenue $2.0M; ublituximab BLA for RMS submitted","bullets":["Net loss $85.6M Q3, $254.8M nine months; ex-stock comp net loss $71.6M and $207.8M.","Product revenue $2.0M Q3, $4.3M YTD from UKONIQ launch (approx 7 months post-approval).","BLA for ublituximab submitted for RMS; PDUFA date for U2 in CLL set for March 25, 2022.","Cash $381.4M as of Sept 30; expected to fund operations into 2023.","R&D $52.0M and SG&A $34.9M in Q3; costs increased due to regulatory submissions and launch."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-21-014445","json":"https://secwatch.observer/filing/0001558370-21-014445.json","markdown":"https://secwatch.observer/filing/0001558370-21-014445.md","text":"https://secwatch.observer/filing/0001558370-21-014445.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1001316/000155837021014445/0001558370-21-014445-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1001316/000155837021014445/tgtx-20211104x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T12:28:53.634904+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}